Different IMRT solutions vs. 3D-Conformal Radiotherapy in early stage Hodgkin’s lymphoma: dosimetric comparison and clinical considerations

Fiandra, Christian; Filippi, Andrea Riccardo; Catuzzo, Paola; Botticella, Angela; Ciammella, Patrizia; Franco, Pierfrancesco; Borca, Valeria Casanova; Ragona, Riccardo; Tofani, Santi; Ricardi, Umberto

doi:10.1186/1748-717X-7-186

Table 2 Comparison of mean dosimetric parameters computed for 3D-CRT, TD, B-VMAT, VMAT and HT

From: Different IMRT solutions vs. 3D-Conformal Radiotherapy in early stage Hodgkin’s lymphoma: dosimetric comparison and clinical considerations

Variable	Objectives	3D-CRT	TD	B-VMAT	VMAT	HT
PTV
Volume (cm³)	428.7 ± 195.6
D_Mean	30	30.6±0.7^b,e	30.0±0.1^a,c,d	30.4±0.2^b,e	30.4±0.2^b,e	29.9±0.1^a,c,d
V_{90% (%)}	99	98.2±1.0^b,d,e	99.2±0.7^a,c,d	98.3±1.2^b,e	98.6±1.1^b,e	99.1±0.2^a,c,d
V_{95% (%)}	95	94.8±0.5^b,d,e	97.4±1.7^a,c,d,e	95.5±2.3^b	95.4±1.7^b	95.9±0.7^a,b
V_{107% (%)}	<1	5.0±5.2^b,d,e	0.02±0.03^a,c,d,e	5.5±3.8^b,e	5.50±3.80^b,e	0.3±0.28^a,b,c,d
CN_{95% (%)}	1	0.30±0.1^c,d,e	0.30±0.1^c,d,e	0.67±0.1^a,b,d,e	0.76±0.02^a,b,c	0.77±0.06^a,b,c
HI	0	0.30±0.1^b,c,d,e	0.10±0.03^a,c,d,e	0.20±0.1^a,b,e	0.16±0.04^a,b,e	0.07±0.01^a,b,c,d
Lung
D_mean(Gy)	-	6.6±2.6	6.3±2.7	5.9±2.5	6.4±2.5	5.9±2.2
V_{5Gy (%)}	50	29.3±12.4^b,c,d,e	26.4±11.6^a,c,d,e	31.3±14.3^a,b,d,e	39.0±15.6^a,b,c	37.0±12.6^a,b,c
V_{10Gy (%)}	33	22.6±9.4^d	21.9±9.6^d	20.8±10.0^d	25.6±13.3^a,b,c,e	20.6±11.0^d
V_{15Gy (%)}	-	18.6±7.6^c,d,e	18.5±8.2^c,d,e	15.3±8.0^a,b,e	15.0±10.6^a,b,e	12.8±7.5^a,b,c,d
V_{20Gy (%)}	-	15.2±6.2^c,d,e	15.6±6.9^c,d,e	11.3±6.7^a,b,d,e	8.8±6.3^a,b,c,	7.6±4.5^a,b,c
V_{30Gy (%)}	-	3.5±2.7^b,c,d,e	0.7±0.5^a	0.8±0.8^a	0.3±0.3^a	0.1±0.3^a
Breast
D_mean(Gy)	-	1.0±0.4^c	0.9±0.9^c	0.7±0.3^a,b,d,e	0.9±0.4^c	1.2±0.9 ^c
V_{4Gy (%)}	50	4.5±2.3^d,e	3.7±4.2^d,e	4.6±3.0^d,e	6.2 ±4.7^a,b,c	5.4±5.5^a,b,c
V_{10Gy (%)}	33	2.5±1.4^c,d,e	2.4±3.0^c,d,e	1.1±1.0^a,b	1.2±1.1^a,b	1.4±1.8^a,b
V_{15Gy (%)}	-	1.4±0.7^c,d,e	1.6±2.2^c,d,e	0.4±0.4^a,b	0.3±0.4^a,b	0.6±1.0^a,b
V_{20Gy (%)}	-	0.9±0.5^c,d	1.3±1.9^c,d	0.1±0.1^a,b	0.1±0.1^a,b	0.2±0.5^a,b
V_{30Gy (%)}	-	0.2±0.3^c,d,e	0.6±1.0^c,d,e	0^a,b	0^a,b	0^a,b
Thyroid
D_mean(Gy)	-	17.7±4.5^c,d,e	17.3±5.1^c,d,e	13.5±6.3^a,b	13.5±5.3^a,b	14.4±5.5^a,b
V_{18Gy (%)}	50	45.9±18.1^c,d,e	51.3±19.2^c,d,e	35.2±21.6^a,b	33.4±18.8^a,b	38.2±23.0^a,b
V_{25Gy (%)}	33	32.0±14.4^c,d,e	32.9±14.6^c,d,e	22.2±15.8^a,b	21.3±14.7^a,b	24.5±19.8^a,b
Coronary Ostia
D_mean(Gy)	-	22.1±9.9^c,d,e	19.8±9.3^c,d,e	15.7±7.9^a,b	15.9±8.9^a,b	16.4±8.4^a,b
V_{20Gy (%)}	100	73.5±40.8^c,d,e	59.1±37.7^c,d,e	43.1±32.6^a,b	44.0±34.3^a,b	44.3±34.2^a,b
Heart
D_mean(Gy)	-	5.1±4.0^c,d,e	4.3±3.7^c,d,e	3.5±2.3^a,b	3.1±2.2^a,b	3.8±3.8^a,b
Non target tissue
D_mean(Gy)	-	4.1±1.3	3.8±0.9	3.1±0.7	3.6±0.9	3.90±0.96
Time (min)	-	3.2±1.1^b,c,d,e	4.4±1.1^a,c,d,e	12.0±2.8^a,b,d,e	6.2±1.3^a,b,c,e	7.2±1.6^a,b,c,d

Statistically significant differences (p<0.05) for each technique versus alternatives are reported: ^aTest vs 3D-CRT; ^b Test vs TD; ^c Test vs B-VMAT; ^d Test vs VMAT; ^e Test vs HT.

Back to article page

ISSN: 1748-717X

Contact us

Submission enquiries: marjoshua.jemina@springernature.com
General enquiries: info@biomedcentral.com

Radiation Oncology

Contact us